Skip to main content

Table 3 Characteristics of patients who did or did not reach the target PBG

From: Improvement of both fasting and postprandial glycemic control by the two-step addition of miglitol and mitiglinide to basal insulin therapy: a pilot study

 

Patients who reached the target PBG using this protocol(N = 14)

Patients who failed to reach the target PBG

Age (years)

67.0 (55.5-70.5)

78

61

Sex (men/women)

10/4

man

woman

BMI (kg/m2)

25.0 (21.8-27.8)

28.0

22.1

Duration of diabetes (years)

13.0 (7.0-21.5)

12

40

HbA1c (%)

9.2 (8.7-11.2)

8.3

8.2

Glycated albumin (%)

23.0 (20.2-29.4)

21.1

19.8

eGFR (mL/min/1.73 m2)

70.5 (58–84.2)

70.0

67.2

Urinary C-peptide excretion (μg/day)

43.5 (24.8-69.6)

67.4

14.4

C-peptide

   

(Glucagon stimulated test)

   

at 0 minutes (ng/mL)

0.9 (0.75-1.45)

1.9

0.4

at 6 minutes (ng/mL)

2.3 (1.45-2.9)

3.0

0.8

Δ (ng/mL)

1.1 (0.65-1.40)

1.1

0.4

Insulin glargine (units/day)

14 (8.5-18.5)

12

13

Insulin glargine (units/kg)

0.2 (0.17-0.26)

0.15

0.23

MAGE at the final CGM evaluation

60.5 (46.9-69.2)

61.3

87.6

(N = 12)

  

M-value at the final SMBG evaluation

8.4 (4.3-14.1)

24.2

18.0

  1. Median (interquartile range).